This study aimed to identify which graft product subset of CD34 þ cells might be the most predictive of early hematopoietic recovery following allogeneic peripheral SCT (allo-PBSCT). The relationship between the number of 'mature' subsets of CD34
Introduction
PBSC are increasingly used as the source for CD34 þ hematopoietic progenitor cells in allogeneic peripheral blood SCT (allo-PBSCT) and these stem cells are generally used with a reduced-intensity conditioning regimen. [1] [2] [3] [4] The mobilization of CD34 þ into peripheral blood in normal donors seems to be safe, without major short-term complications, but it could be associated with cardiac complications in elderly patients and there are not enough data regarding the long-term safety of this drug. 5 Allogeneic transplantation with PBSC is associated with faster neutrophil and platelet engraftment in the recipient, [1] [2] [3] 6 but PBSC seem to be responsible for a higher incidence of chronic GVHD compared with BM stem cells. 7 Engraftment kinetics in allo-PBSCT depend on the disease status at transplantation, on the number and efficiency of the stem cells in the graft, on the conditioning regimen and on GVHD prophylaxis. [1] [2] [3] 6 CD34 þ cells consist of a heterogeneous population including the early uncommitted fraction as well as different subsets committed to one or another lineage. [8] [9] [10] [11] Hence, defining the CD34 subset that is most predictive of engraftment and its threshold value would be of the utmost importance. Several authors have reported that as in autologous PBSCT, 12, 13 the rapid neutrophil and platelet engraftment in the allogeneic setting depends on the overall dose of CD34 þ cells infused, high CD34 þ cell doses generally resulting in a quicker engraftment. 2, 3 Many studies [14] [15] [16] [17] have reported a correlation between the total number of CD34 þ cells infused or the subsets of CD34 þ cells and early and long-term engraftment in acute leukemia, non-Hodgkin's lymphoma, multiple myeloma after autologous transplantation, but little information is available regarding the influence of the CD34 þ total cell dose or CD34 þ subsets on engraftment in allo-PBSCT. [18] [19] [20] In this study, we analyzed the number of 'immature' and 'mature' stem cells using monoclonal antibodies CD33, CD38, DR and CD133, and examined the relationship between the number of these cells and early hematopoietic reconstitution in a homogeneous group (for disease, number and type of pre transplant chemotherapy cycles, conditioning regimen and GVHD prophylaxis) of 30 AML patients after allo-PBSCT from an HLA-identical sibling.
Patients and methods
A total of 30 consecutive AML patients in the first CR (14 men and 16 women with a mean age of 38 years; range: 15-58), undergoing allo-PBSCT from an HLA-identical sibling, were included in this study. The main clinical and biological characteristics of both patients and donors are specified in Table 1 After incubation, RBC were lysed and cells were analyzed by fluorescence-activated cell sorting (FACScan; Becton Dickinson Immunocytometry System, San Jose, CA, USA) using the CellQuest Software. 21 The influence of short-term engraftment on the dose of CD34 þ and CD34 þ subsets, patient's age, donor/recipient sex match, blood group (ABO) incompatibility and CMV serology was analyzed. For short-term engraftment, the neutrophils and platelets count recovery after allo-SCT was recorded; time to neutrophil engraftment was defined as the first of 3 consecutive days in which the absolute neutrophils count was40.5 Â 10 9 /l; time to platelets engraftment was defined as the first of 7 consecutive days in which the transfusionindependent platelet count was 420 Â 10 9 /l. No correlation between long-term engraftment and CD34 þ cell subsets was considered because of the influence in long-term engraftment of GVHD and therapy for GVHD, CMV infection and disease and disease relapse.
Statistical analysis
Pearson's test was used to correlate the number of mature and immature CD34 þ cells with early engraftment. The influence on short-term engraftment on patient age, donor/ recipient sex-match, donor/recipient ABO incompatibility and CMV serology was also analyzed; for this purpose the Mann-Whitney U-test, Spearman's correlation and w 2 test were used. For all statistical analyses, the Statistical Package for social sciences (SPSS Inc., Chicago, IL, USA), version 11.5 for Windows, was used. Differences were considered statistically significant at P-values of o0.05. Table 2 shows the composition of the infused dose of CD34 þ cells, subset of CD34 þ cells and lymphocyte subpopulations. The median number of CD34 þ cells infused was 4.6 Â 10 6 /kg (range: 3-8.8); the percentage of immature CD34 was 40% for CD34 þ /CD33À, 65% for CD34 þ /CD38À, 5% for CD34 þ /DRÀ and 70% for CD34 þ /CD133 þ ; this translates into a median of 1.8 Â Subsets of CD34 þ cells and engraftment in allo-PBSCT D Pastore et al (Table 3 ) Eleven patients (42%) developed acute GVHD (aGVHD; median onset 35 days; range: 26-58), of whom two developed aGVHD grade III-IV and nine GVHD grade I-II. There was no significant impact of CD34 þ cells or any subsets on the occurrence or severity of aGVHD.
Results
The most important CD34 þ subset predicting early engraftment was CD34 þ /CD133 þ that was inversely correlated with the days to engraftment of neutrophils (40.5 Â 10 9 /l; r ¼ À0.82, P ¼ 0.02; Figure 1 ) and platelets (420 Â 10 9 /l) (r ¼ À0.60, P ¼ 0.06; Figure 2) ; this correlation was better than total dose of CD34 þ cells and neutrophils (r ¼ À0.70, P ¼ 0.04; Figure 3 ) and platelet (r ¼ À0.56, P ¼ 0.07) engraftment (Figure 4) . Also, as regards the day when the neutrophil count 41 Â 10 9 l and platelet count 450 Â 10 9 /l were achieved, the correlation of CD34 þ /CD133 þ cells (r ¼ À0.63, P ¼ 0.05 for neutrophil count; r ¼ À0.77, Po0.04 for platelet count) was better than the total CD34 þ cells (r ¼ À0.57, P ¼ 0.07 for the neutrophil count and r ¼ À0.54, P ¼ 0.07 for the platelets count). No correlation was observed between other mature or immature subsets of CD34 þ cells, lymphocyte subsets and early neutrophil and platelet engraftment. With regard to the threshold dose for early neutrophil engraftment, all 20 patients who received more than 3 Â 10 6 /kg of CD34 þ / CD133 þ had a neutrophil count higher than 0.5 Â 10 9 /l at 12 days (range: 10-13) compared to a median of 14 days (range: 12-16) in 10 patients who received o3 Â 10 6 /kg of CD34 þ /CD133À. The group with a high number of CD34 þ /CD133 þ (43 Â 10 6 /kg) had a shorter period of hospitalization (median 28 days; range: 26-30) compared with the group with a low number of CD34 þ /CD133 þ (o1 Â 10 6 /kg) (median 31 days; range: 29-38). None of the following variables, the presence of mismatched sex pairing, ABO incompatibility and CMV serology, showed an influence on short-term neutrophil and platelet engraftment.
Discussion
CD34 þ cells are a heterogeneous population including early/immature stem cells together with a population of precursors already committed to the different hematopoietic lineages. 9 Hence, defining the CD34 subset that is most predictive of early engraftment and the threshold value could be of the utmost importance. [14] [15] [16] [17] [18] [19] [20] In autologous mobilization, the collection of total CD34 þ cells and CD34 subsets is influenced largely by the disease type, prior chemotherapy treatment, disease status and mobilization chemotherapy. Normal donors mobilized with G-CSF presumably have normal BM and so there are important biological quantitative and qualitative differences between the autologous and allogeneic CD34 subsets. In a previous report, 15 we observed that autologous mobilization in acute leukemia patients produced a low percentage of CD34 þ lacking CD33, DR, CD38 (2.8, 3 and 8.5%, respectively); other studies 14, 16 have confirmed this observation and we suggest that mobilization with the growth factor in normal donors causes the release of more immature CD34 þ cells Subsets of CD34 þ cells and engraftment in allo-PBSCT D Pastore et al than in patients on a chemotherapy-based protocol. In the autologous setting, it has been suggested that enumeration of specific subsets of CD34 þ cells could more accurately predict short-and long-term engraftment after transplantation than the overall total dose of CD34 þ cells infused. [14] [15] [16] Nevertheless, information regarding the role of specific subsets of CD34 þ cells on engraftment in allo-SCT is limited. [18] [19] [20] In the present study, we evaluated the correlation between CD34 þ cell subsets and early neutrophil and platelet engraftment in a homogeneous series (for disease, pre transplant chemotherapy, conditioning regimen and GVHD prophylaxis) of 30 AML patients after allo-PBSCT from HLA-identical siblings. We suggest that the number of immature CD34 þ subsets expressing CD133 predicts early neutrophil and platelet engraftment better than the total CD34 þ cell dose, without influencing the incidence of aGVHD. Menendez et al. 18 reported that the overall number of CD34 cells and myelomonocytic CD34 þ infused was strongly associated with neutrophil recovery and the number of myelomonocytic-committed CD34 þ cells infused significantly influenced the risk of aGVHD. Another study 19 concluded that in allo-PBSCT, the best predictor of early neutrophil engraftment is the absolute CD34 þ /DRÀ, and of early platelet engraftment is the absolute CD34 þ /CD61 þ cell dose. All these studies examined a heterogeneous population (AML, ALL, multiple myeloma, non-Hodgkin's disease and Hodgkin's disease) after different conditioning regimens of myeloablative and non-myeloablative allo-PBSCT and with different GVHD prophylaxis. Pecora et al. 13 reported a correlation between CD34 þ /CD33À cells and engraftment kinetics in 410 cancer patients, but they examined a heterogeneous population (breast cancer, ovarian cancer and hematological malignancies). As all patients received G-CSF post transplant, there remains the possibility that without the use of the growth factor, the significant relationship observed between the dose of CD34 þ / CD33À cells and platelets engraftment might be altered.
In our experience with a homogeneous population of AML patients, after the same conditioning and GVHD prophylaxis, the best predictor of early neutrophil and platelet engraftment is the absolute CD34 þ /CD133 þ cell dose.
CD133 is known to be a marker of primitive hematopoietic stem and progenitor cells; 22 CD133 þ cells appear to be ancestral to CD34 þ cells, especially as the latter can be generated in vitro from CD133 þ CD34À cells and experimental data demonstrate that higher proliferating and self-replicating CD133 þ cells display a higher capacity of CD133 þ /CD34 þ cells in comparison to CD133-CD34 þ cells. 22, 23 Populations of CD133 þ are also able to repopulate SCID mice and CD133 þ selected cells are currently under investigation for use in SCT. [24] [25] [26] [27] In summary, our results suggest that in myeloablative allo-PBSCT, a high number of CD34 þ /CD133 þ leads to rapid neutrophil and platelet engraftment with no increased risk of aGVHD. These preliminary findings need to be confirmed in larger series of patients with the use of multivariate analysis integrating patients' characteristics and transplant modalities; they could be useful in the evaluation of all hematological malignancies after allo-PBSCT. In the clinical setting, in allogeneic transplantation with a borderline or suboptimal CD34 cell dose, measurement of the CD34 þ /CD133 þ cell number may provide additional information about graft quality. /l (days) and number of CD34 þ Â 10 6 /kg infused (r ¼ À0.56, P ¼ 0.07).
